These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21718647)

  • 1. [CYLD deubiquitinase as a recurrent target in oncogenic processes].
    Bonnet M; Courtois G
    Med Sci (Paris); 2011; 27(6-7):626-31. PubMed ID: 21718647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene.
    Oiso N; Mizuno N; Fukai K; Nakagawa K; Ishii M
    Br J Dermatol; 2004 Nov; 151(5):1084-6. PubMed ID: 15541090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYLD: a deubiquitination enzyme with multiple roles in cancer.
    Massoumi R
    Future Oncol; 2011 Feb; 7(2):285-97. PubMed ID: 21345146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.
    Hunstig F; Schulz S; Nieten I; Froster U; Boltze C; Schliemann S; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):845-8. PubMed ID: 26660106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
    Sun SC
    Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large germline deletions of the CYLD gene in patients with Brooke-Spiegler syndrome and multiple familial trichoepithelioma.
    Vanecek T; Halbhuber Z; Kacerovska D; Martinek P; Sedivcova M; Carr RA; Slouka D; Michal M; Kazakov DV
    Am J Dermatopathol; 2014 Nov; 36(11):868-74. PubMed ID: 25347032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trichoepithelioma.
    Johnson H; Robles M; Kamino H; Walters RF; Lee A; Sanchez M
    Dermatol Online J; 2008 Oct; 14(10):5. PubMed ID: 19061604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype-genotype correlations for clinical variants caused by CYLD mutations.
    Nagy N; Farkas K; Kemény L; Széll M
    Eur J Med Genet; 2015 May; 58(5):271-8. PubMed ID: 25782638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
    Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
    Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CYLD p.R758X worldwide recurrent nonsense mutation detected in patients with multiple familial trichoepithelioma type 1, Brooke-Spiegler syndrome and familial cylindromatosis represents a mutational hotspot in the gene.
    Farkas K; Deák BK; Sánchez LC; Martínez AM; Corell JJ; Botella AM; Benito GM; López RR; Vanecek T; Kazakov DV; Kromosoeto JN; van den Ouweland AM; Varga J; Széll M; Nagy N
    BMC Genet; 2016 Feb; 17():36. PubMed ID: 26861065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multiple familial trichoepithelioma: a new CYLD gene mutation].
    Duparc A; Lasek-Duriez A; Wiart T; Duban-Bedu B; Gosset P; Modiano P
    Ann Dermatol Venereol; 2013 Apr; 140(4):274-7. PubMed ID: 23567228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aspirin against cylindromatosis? Molecular functions of the CYLD tumor suppressor].
    Funk JO
    Hautarzt; 2004 Mar; 55(3):327-8. PubMed ID: 15029443
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
    Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
    In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
    Almeida S; Maillard C; Itin P; Hohl D; Huber M
    J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel missense mutation of the CYLD gene identified in a Hungarian family with Brooke-Spiegler syndrome.
    Nagy N; Farkas K; Kinyo A; Nemeth IB; Kis E; Varga J; Bata-Csorgo Z; Kemeny L; Szell M
    Exp Dermatol; 2012 Dec; 21(12):967-9. PubMed ID: 23171463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recurrent R936X mutation of CYLD gene in a Chinese family with multiple familial trichoepithelioma.
    Zhang QG; Liang YH
    Indian J Dermatol Venereol Leprol; 2015; 81(2):192-4. PubMed ID: 25751345
    [No Abstract]   [Full Text] [Related]  

  • 18. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
    Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
    Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYLD in ubiquitin signaling and tumor pathogenesis.
    Ikeda F; Dikic I
    Cell; 2006 May; 125(4):643-5. PubMed ID: 16713556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
    Parren LJMT; Giehl K; van Geel M; Frank J
    Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.